Drug Database
TE

tetrahydrocannabinol + cannabidiol (MXC1:1)

✓ Approved

Argent BioPharma · CNR1

什么是 tetrahydrocannabinol + cannabidiol?

tetrahydrocannabinol + cannabidiol 是一种治疗药物,由Argent BioPharma研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名MXC1:1
公司Argent BioPharma
分子靶点CNR1, HTR1A, TRPV1, GPR55
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

tetrahydrocannabinol + cannabidiol 作用于 4 个分子靶点:

CNR1cannabinoid receptor 1 (CNR, CB1A)
HTR1A5-hydroxytryptamine receptor 1A (PFMCD, 5-HT1A)
TRPV1transient receptor potential cation channel subfamily V member 1 (VR1)
GPR55G protein-coupled receptor 55 (LPIR1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

tetrahydrocannabinol + cannabidiol 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersAbdominal pain✓ Approved
Nervous system disordersMuscle spasticity✓ Approved

相关研究文献

PubMedJournal of affective disorders reports2026-11-17

Effectiveness and Safety of Cannabis on Anxiety Treatment Outcomes: A Systematic Review.

Kotecha Pareeta P, Perez-Vilar Silvia S, Lloyd Joshua J, Sandhu Sukhminder K SK et al.

We assessed controlled non-interventional studies and randomized clinical trials (RCTs) evaluating THC-containing cannabis' safety and effectiveness for anxiety. We searched PubMed, Embase, APA PsychInfo, and Cochrane databases in February 2023 for clinical studies that reported patient-level controlled quantitative assessments of anxiety outcomes following cannabis treatment. Exclusion criteria included: publication before 2000, in non-English language, assessment of topical treatment or containing <0.3% tetrahydrocannabinol, and FDA-approved products. We assessed risk of bias via RoB2/ROBINS-I, and rated evidence quality using the GRADE approach. PROSPERO:CRD42023411999. From 6,453 search records, 4 RCTs and 1 observational study met inclusion criteria. All studies involved patients with severe comorbid medical conditions, with anxiety assessed as a secondary outcome, limiting generalizability to primary anxiety disorders. Interventions included THC-rich cannabis oil for fibromyalgia, cannabinoids for obsessive-compulsive disorder (OCD), cannabidiol (CBD)-enriched extracts for Parkinson's disease, nabiximols (THC:CBD 1:1) for multiple sclerosis (MS), and cannabis for chronic non-cancer pain. Anxiety was measured via self-reported scales. Due to heterogeneity in anxiety measures, results were synthesized narratively. Compared with placebo, the OCD RCT showed significant anxiety worsening [4.31 (1.70, 6.92)]; the Parkinson's disease RCT non-significant improvement [-0.82 (-1.97, 0.33)], and the fibromyalgia and MS RCTs show no significant effects [0.38 (-2.91, 3.67); -2.00 (-7.51, 3.51)]. The pain observational study reported no initial significant effect on anxiety -0.30 (-1.53, 0.93). Quality of life (QoL) worsened with THC in Parkinson's [-0.14 (-0.23, -0.04)] and showed non-significant improvement in MS [0.35 (-1.09, 1.79)]. The evidence quality was rated low to moderate. Evidence on THC-containing cannabis' effects on anxiety is limited and inconsistent, with heterogeneous measures and mixed findings preventing meaningful quantitative synthesis. Across studies, no consistent evidence of benefit was observed. Higher-quality studies with standardized outcomes are needed to clarify their impact on anxiety and quality of life. Evidence quality was rated as low to moderate, driven by small sample sizes, short durations, and limited generalizability.

PMID 43041801
阅读全文 →
PubMedNatural product research2026-11-17

Quantitative NMR-based profiling and chemometric analysis of phytocannabinoids in Moroccan Cannabis sativa extracts (beldia variety).

Héritier Uwikunda Serondo S, Metouekel Amira A, Hamdoun Ghanem G, El Amri Hamid H et al.

Cannabis sativa L. has been used for both economic and medical purposes, due to its numerous bioactive compounds called phytocannabinoids and non-cannabinoids, such as the psychoactive Δ9-tetrahydocannabinol (Δ9-THC) as well as the non-psychoactive cannabidiol (CBD). With the legalisation of cannabis in Morocco in 2021, there is a pressing need for reliable and efficient methods to quantify cannabinoid content in local cultivars. This work proposes the use of the 1D CPMG NMR technique combined with multivariate statistical analysis to identify and quantify five major cannabinoids in 17 extracts collected from different sites in northern Morocco. The results obtained revealed the predominance of THC (average = 7.84 mmol·L-1) and CBD (average = 0.98 mmol·L-1) which is consistent with known cannabinoid biosynthetic pathways of phytocannabinoids. The developed method enables accurate measurement of cannabinoid levels in various samples, making it valuable for the cannabis industry.

PMID 43043372
阅读全文 →
PubMedChemical communications (Cambridge, England)2026-11-17

Photochemical dearomatization of indoles via their excited states.

Shen Wen-Jie WJ, Cheng Yuan-Zheng YZ, You Shu-Li SL

Indoline frameworks are widely encountered in bioactive natural products and pharmaceuticals, making their efficient construction an enduring objective in synthetic chemistry. Dearomatization of indoles has emerged as a particularly powerful strategy for accessing these three-dimensional, highly functionalized scaffolds from readily available aromatic precursors. In this context, photochemical activation has opened new avenues for indole dearomatization by harnessing the distinctive reactivity of electronically excited states and enabling bond-forming processes that are often difficult to achieve under conventional thermal conditions. This review highlights recent advances in photochemical dearomatization of indoles, with the discussion organized into intramolecular and intermolecular transformations.

PMID 43041497
阅读全文 →
PubMedHCA healthcare journal of medicine2026-11-17

Pharmacovigilance as an Act of Awareness and Mindfulness.

Silas Mahima M, Toklu Hale Z HZ

Description The term "pharmacovigilance" defines the activities related to the collection, detection, assessment, monitoring, and prevention of adverse reactions due to pharmaceuticals. While it is often framed as a technical and regulatory discipline, it can also be understood through a more reflective lens as a form of mindfulness practice. At its core, pharmacovigilance requires a way of thinking that closely mirrors mindfulness, including sustained attention, openness to uncertainty, and deep awareness of human experience. Viewing pharmacovigilance in this way reframes it not just as a safety mechanism, but as a thoughtful, patient-centered approach to medicine.

PMID 43042117
阅读全文 →
PubMedDrugs2026-11-17

Oveporexton: First Approval.

Brown Michael B MB

Oveporexton (ORZEYFULTM) is an oral selective orexin receptor 2 agonist developed by Takeda Pharmaceuticals Inc. for the treatment of narcolepsy type 1 (NT1). Oveporexton received its first approval in China on 22 July 2026 for the treatment of adolescents aged ≥ 16 years and adults with NT1. Subsequently, oveporexton was approved on 5 August 2026 in the USA and on 24 August 2026 in Japan for adults with NT1. Targeting the underlying orexin deficiency in NT1, oveporexton is the first and only agent approved for the treatment of NT1 addressing the full range of symptoms which define the condition. Additional global filings and phase III clinical trials are ongoing. This article summarizes the milestones in the development of oveporexton leading to this first approval for NT1.

PMID 43040185
阅读全文 →
PubMedEpileptic disorders : international epilepsy journal with videotape2026-11-17

Real-world safety profiles of newer antiseizure medications: A pharmacovigilance study based on FDA Adverse Event Reporting System database.

He Zimeng Z, Li Tongyue T, Chang Yuyan Y, Liu Yang Y et al.

This study aimed to systematically evaluate and compare the post-marketing safety of four newer antiseizure medications (ASMs)-brivaracetam (BRV), cannabidiol (CBD), cenobamate (CNB), and fenfluramine (FFA). A pharmacovigilance study was conducted using data from the FAERS database (Q1 2016-Q4 2024). Disproportionality analyses were performed to detect adverse event (AE) signals using three algorithms. Subgroup analyses were stratified by age, sex, reporter, and treatment strategy. We employed multivariable logistic regression, adjusted for covariates including age, sex, weight, dose, and concomitant medications, to validate associations between ASMs and specific AEs and to identify potential influencing factors. Bayesian network analysis was conducted to explore conditional dependencies among variables. Hospitalization risk was evaluated based on system organ classes. After data cleaning, 13 763 reports were included. We identified 308 positive preferred term (PT) signals. Seizure-related AEs were frequently reported. All four ASMs had the PT of seizure cluster, with each exhibiting distinct AE profiles: BRV with psychiatric disorders, CBD with gastrointestinal events, CNB with visual dysfunction, and FFA with valvular heart disease (VHD). Children had higher reporting odds of seizure with BRV and CBD, while reporting odds of FFA-related VHD were lower in children; polytherapy was associated with higher reporting odds of somnolence, and AE reporting patterns varied by reporter source. Both CBD-related gastrointestinal events and FFA-related cardiac events exhibited dose-dependent effects. Infection-related AEs were associated with higher odds of hospitalization for multiple ASMs. This study comprehensively characterizes the safety profiles of newer ASMs and highlights the importance of tailored AE monitoring based on specific ASM and patient characteristics.

PMID 43042732
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多tetrahydrocannabinol + cannabidiol